Response Under 37 CFR 1.116
Expedited Procedure
Examining Group 1600

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

1. (Currently Amended) A method of increasing fibrinolysis levels in a subject, the method comprising:

identifying a <u>human</u> subject with at least one 4G allele and/or genotype at the plasminogen activator inhibitor-1 (PAl-1) gene promoter site, and at least one I allele and/or genotype at the <u>tissue plasminogen activator</u> (t-PA) gene locus and

engaging the subject in exercise training for a period of time sufficient to increase fibrinolysis in the subject.

- 2. (Original) The method of claim 1, wherein the subject has a 4G/5G genotype.
- 3. (Original) The method of claim 1, wherein the subject has a 4G/4G genotype.
- 4. (Original) The method of claim 1, wherein the exercise training comprises extensive exercise.
- 5. (Original) The method of claim 1, wherein the exercise training comprises moderate exercise.
- 6. (Original) The method of claim 1, wherein the exercise training comprises limited exercise.
- 7. (Currently Amended) A method of preventing cardiovascular disease in a <u>human</u> subject, the method comprising:

identifying a subject with at least one 4G aHele and/or genotype at the plasminogen activator inhibitor-1 (PAl-1) gene promoter site, and at least one 1 allele and/or genotype at the <u>tissue plasminogen activator</u> (t-PA) gene locus and

engaging the subject in exercise training for a period of time sufficient to prevent cardiovascular disease in the subject.

Application No. 10/612,894 Paper dated August 16, 2007 Attorney Docket No. 5458-071900

## Response Under 37 CFR 1.116 Expedited Procedure Examining Group 1600

- 8. (Previously Presented) The method of claim 7, wherein the subject has a 4G/5G genotype.
- 9. (Previously Presented) The method of claim 7, wherein the subject has a 4G/4G genotype.
- 10. (Previously Presented) The method of claim 7, wherein the exercise training comprises extensive exercise.
- 11. (Previously Presented) The method of claim 7, wherein the exercise training comprises moderate exercise.
- 12. (Previously Presented) The method of claim 7, wherein the exercise training comprises limited exercise.
- 13. (Currently Amended) A method of ameliorating cardiovascular disease in a <a href="https://human.subject.suffering">human</a> subject suffering from cardiovascular disease, the method comprising:

identifying a subject with at least one 4G allele and/or genotype at the plasminogen activator inhibitor-1 (PAl-1) gene promoter site, and at least one I allele and/or genotype at the <u>tissue plasminogen activator</u> (t-PA) gene locus and

engaging the subject in exercise training for a period of time sufficient to ameliorate cardiovascular disease in the subject.

- 14. (Previously Presented) The method of claim 13, wherein the subject has a 4G/5G genotype.
- 15. (Previously Presented) The method of claim 13, wherein the subject has a 4G/4G genotype.
- 16. (Previously Presented) The method of claim 13, wherein the exercise training comprises extensive exercise.
- 17. (Previously Presented) The method of claim 13, wherein the exercise training comprises moderate exercise.
- 18. (Previously Presented) The method of claim 13, wherein the exercise training comprises limited exercise.

3

Application No. 10/612,894 Paper dated August 16, 2007 Attorney Docket No. 5458-071900 Response Under 37 CFR 1.116 Expedited Procedure Examining Group 1600

- 19. (Previously Presented) The method of claim 1, wherein the subject has a I/I genotype.
- 20. (Previously Presented) The method of claim 1, wherein the subject has a I/D genotype.
- 21. (Withdrawn) A method of increasing fibrinolysis levels in a subject, the method comprising:

identifying a subject with at least one I allele and/or genotype at the (t-PA) gene locus; and

engaging the subject in exercise training for a period of time sufficient to increase fibrinolysis in the subject.

- 22. (Withdrawn) The method of claim 21, wherein the subject has a I/I genotype.
- 23. (Withdrawn) The method of claim 21 wherein the subject has a I/D genotype.
- 24. (Withdrawn) The method of claim 21, wherein the exercise training comprises extensive exercise.
- 25. (Withdrawn) The method of claim 21, wherein the exercise training comprises moderate exercise.
- 26. (Withdrawn) The method of claim 19, wherein the exercise training comprises limited exercise.
- 27. (Withdrawn) A method of preventing or ameliorating cardiovascular disease in a subject, the method comprising:

identifying a subject with at least one I allele and/or genotype at the (t-PA) gene locus; and

engaging the subject in exercise training for a period of time sufficient to prevent cardiovascular disease in the subject.